MedPath

T-116_Procera-Bridge Zirconia - A Clinical Study

Not Applicable
Completed
Conditions
Partial Edentulism
Registration Number
NCT02186808
Lead Sponsor
Nobel Biocare
Brief Summary

The objective of the study is to evaluate the clinical performance of Procera® Bridge Zirconia veneered with NobelRondo Zirconia.

Detailed Description

The study was designed to be an open, 5-year, prospective, multi-center clinical post-market study. The objectives of this clinical study were that industrial centrally produced 3- or 4-unit bridges of yttrium-oxide partially-stabilized (Y-TZP) zirconia (Procera Zirconia) in combination with the veneering ceramic material NobelRondo will show sufficient CDA ratings (90% R+S) and a sufficient survival rate after 1 and 5 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible
  • Indication: same indication as for metal supported bridges
  • Obtained informed consent from the patient

Exclusion criteria

  • Currently known alcohol, drug or medication abuse, judged by the investigator, which might influence the follow-up program
  • Patients where a bridge part connection area of 3 mm of diameter is not possible to obtain (short clinical crowns)
  • Mobility of the abutment teeth exceeding grade I
  • Patients with pathologic pocket formation at abutment teeth
  • Patients with complete dentures in the opposing jaw
  • Patients with a removable partial denture in the same jaw
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Success Rate of Bridge Procera Bridge Zirconiaprosthesis delivery, 1 year

The CDA index (1) is Romeo or Sierra at delivery and remains so up to 1 year post loading.

Secondary Outcome Measures
NameTimeMethod
Success Rate of Bridge Procera Bridge Zirconiaprosthesis delivery, 5 years

The CDA index (1) is Romeo or Sierra at delivery and remains so 5 year post loading.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.